Valuation: PREDILIFE

Market Cap 35.12L 39.33L 39.33L 32.67L 29.72L 56.11L 38Cr 56.35L 3.93Cr 1.54Cr 19Cr 1.48Cr 1.44Cr 62Cr P/E 2024
-3.18x
P/E 2025 -3.01x
Enterprise Value 82.9L 92.82L 92.82L 77.12L 70.14L 1.32Cr 90Cr 1.33Cr 9.28Cr 3.64Cr 46Cr 3.49Cr 3.41Cr 146.97Cr EV / Sales 2024
34.5x
EV / Sales 2025 19.3x
Free-Float
48.75%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 56 01/01/2004
Chief Tech/Sci/R&D Officer - 01/01/2007
General Counsel - 01/01/2016
Director TitleAgeSince
Chairman 56 01/01/2004
Director/Board Member 46 01/01/2018
Director/Board Member 58 01/01/2018
Change 5-day change 1-year change 3-year change Capi.($)
-2.59%-5.70%+39.83%+82.45% 7.06TCr
+3.23%-10.67%+4.87%+55.97% 5.1TCr
+1.56%+1.17%+5.15%+33.38% 4.81TCr
+0.39%+0.65%+28.02%+30.24% 4.28TCr
+0.87%-8.17%+298.53%+645.03% 4.07TCr
+1.24%-1.01%+5.56%+105.14% 4.03TCr
-2.13%-1.64%+7.51%+50.31% 3.06TCr
-0.46%-1.28%+31.47%+19.93% 2.82TCr
+5.32%+0.06%-7.20%-11.30% 2.44TCr
Average +0.83%-2.66%+45.97%+112.35% 4.18TCr
Weighted average by Cap. +0.56%-2.94%+47.30%+116.51%

Financials

2024 2025
Net sales 5L 6L 6L 5L 4L 8L 5.34Cr 8L 55.22L 21.64L 2.72Cr 20.74L 20.28L 8.74Cr 8L 9L 9L 8L 7L 13.35L 9.06Cr 13.41L 93.58L 36.67L 4.62Cr 35.14L 34.37L 15Cr
Net income -42.65L -47.75L -47.75L -39.67L -36.09L -68.13L -46Cr -68.43L -4.77Cr -1.87Cr -24Cr -1.79Cr -1.75Cr -76Cr -39.34L -44.05L -44.05L -36.6L -33.29L -62.86L -43Cr -63.13L -4.41Cr -1.73Cr -22Cr -1.65Cr -1.62Cr -70Cr
Net Debt 35.38L 39.62L 39.62L 32.92L 29.94L 56.53L 38Cr 56.77L 3.96Cr 1.55Cr 20Cr 1.49Cr 1.46Cr 63Cr 47.78L 53.5L 53.5L 44.44L 40.43L 76.33L 52Cr 76.66L 5.35Cr 2.1Cr 26Cr 2.01Cr 1.96Cr 85Cr
Logo PREDILIFE
PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women, and over 300,000 French women. PREDILIFE also develops multi-pathology tests to screen for colon, prostate and lung cancer, melanoma and cardiovascular risks.
Employees
-